Boston Scientific (BSX) Q1 2026 (USD): Adj. EPS 0.80 (exp. 0.79), Revenue 5.2bln (exp. 5.17bln); Next Qtr. Adj. EPS 0.82-0.84 (exp. 0.86); Current FY EPS 3.34-3.41 (prev. guided 3.43-3.49, exp. 3.46)

Boston Scientific's Q1 results slightly beat expectations on both adjusted EPS and revenue, suggesting solid performance thus far. However, the guidance for next quarter and the current fiscal year has been lowered, which could raise concerns about future growth. This mixed outcome may impact market sentiment around BSX and the healthcare equipment sector more broadly, prompting a cautious stance among investors.